Efficacia e tollerabilità di sacituzumab govitecan nella paziente anziana con carcinoma mammario avanzato triplo negativo

The triple-negative breast carcinoma (TNBC), despite representing a minority of all breast carcinoma cases, poses a significant problem due to its biological aggressiveness and the resulting unfavorable prognosis for affected patients. Until recently, the only therapeutic strategy available was chemotherapy. However, new therapeutic approaches have recently led to an improvement in the natural history of this disease. Among these, the monoclonal antibody-drug conjugate sacituzumab govitecan has been shown to double the survival of the patients under examination. The use of this drug is associated with non-negligible side effects, the management of which must be careful and prompt, especially in the case of elderly patients, who are inherently at higher risk of toxicity related to anticancer therapies but should not be denied the possibility of new and effective treatments. This study will describe the clinical case of an elderly patient with advanced TNBC.